Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 7.5% – Should You Sell?

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) were down 7.5% during mid-day trading on Friday . The company traded as low as $2.46 and last traded at $2.46. Approximately 48,743 shares were traded during mid-day trading, an increase of 18% from the average daily volume of 41,268 shares. The stock had previously closed at $2.66.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH increased their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Price Performance

The company has a 50-day simple moving average of $3.38 and a two-hundred day simple moving average of $3.66.

Insider Buying and Selling

In other Marker Therapeutics news, Director Steve Elms acquired 11,085 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average cost of $3.20 per share, with a total value of $35,472.00. Following the acquisition, the director now owns 325,370 shares in the company, valued at approximately $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Enterprise Associates 16 New bought 554,250 shares of the stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the acquisition, the insider now directly owns 1,625,678 shares in the company, valued at approximately $5,202,169.60. This trade represents a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 17.35% of the stock is owned by insiders.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Invst LLC purchased a new stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned 0.22% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is owned by institutional investors and hedge funds.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.